Finally, in vitro studies with curcumin have also demonstrated that this bioactive compound acts synergistically with 5-fluorouracil plus oxaliplatin, a standard chemotherapy for this malignancy, in inhibiting the growth of HCT-116 and HT-29 cells through attenuation of surface growth factor pathways, specifically EGFRs and insulin-like growth factor-1 receptor (IGF-1R), which are considered to play an important role in the progression of CRC [34]. The gene discussed is IGF1R; the disease is colorectal carcinoma.